Pricing and Price Competition Risks for Immune Cell Therapy
First written in FY2017. . Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022Treatment cost level updatedAnnual report
「The total cost of one course of immune-cell therapy at the medical institutions under contract with us is approximately ¥2 million, although it depends on the type of treatment and other factors that the physician considers appropriate.」
The disclosure on the total cost of one course of immune-cell therapy was updated from approximately ¥1.6 million to approximately ¥2 million. It continues to identify as risks the lack of standardized pricing and the impact of intensified competition on processing fees. - FY2017First statedAnnual report
「The total cost of one course of immune cell therapy at our contracted medical institutions is approximately ¥1.6 million, depending on the type of treatment deemed appropriate by the physician. If the environment for the industrialization of regenerative and cellular medicine develops, new companies enter the market and competition intensifies, leading to price competition for the comprehensive immune cell therapy support service and new businesses, this could affect the Group’s performance.」
The Company discloses approximately ¥1.6 million per course as the treatment cost and identifies the lack of standardized pricing and intensifying competition as risks to service prices.